Lund February 27th 2024 – AegirBio AB is pleased to announce the appointment of Professor Iain L. C. Chapple, BDS, FDSRCPS (Glas), FDSRCS (Edin) Ph.D. CCST (Rest Dent), to the Scientific Advisory Board to support the company’s Oral Health strategy. Professor Chapple, a distinguished dental professional, brings a wealth of experience and expertise to our esteemed board and will be key to AegirBio’s strategy of measuring specific biomarkets in saliva together with its digital platform to improve overall health.

"We are thrilled to welcome Professor Iain Chapple to our Scientific Advisory Board for Oral Health. His unparalleled expertise, leadership, and commitment to advancing dental research aligns perfectly with our mission. Professor Chapple's inclusion will undoubtedly enhance our scientific vision and drive innovation in the pursuit of improved oral health for all," said Marco Witteveen CEO and Board member of AegirBio.

Formerly the Director of Research for the Institute of Clinical Sciences and Head of the Dental School (2016-2020) at Birmingham University, Professor Chapple has authored 13 textbooks and contributed 35 chapters to various publications, showcasing his commitment to advancing knowledge in the field of dentistry. He has been a prominent figure in various dental organizations, having served as the President of the IADR Periodontal Research Group (2006-2007), Treasurer, Secretary General and Scientific Advisory Committee Chair of the European Federation of Periodontology (2007-2013), and President of the British Society of Periodontology (2014-2015), among other significant roles.

His outstanding contributions to periodontal research have earned him prestigious awards, including The Royal College of Surgeons Tomes medal (2011), IADR Distinguished Scientist (2018), and EFP’s Eminence Award (2022). In recognition of his exceptional service to dentistry, Professor Chapple was also awarded an MBE in the 2022 Queens New Year’s Honour’s.

With over 250 published papers, Professor Chapple's research extends beyond traditional periodontics. He leads both a regional periodontal service and a national service for adults with Epidermolysis Bullosa, demonstrating his commitment to advancing oral health on multiple fronts.

Professor Chapple expressed his enthusiasm about joining the Scientific Advisory Board, stating, "I am honoured to be part of AegirBio's mission to advance oral health. I look forward to contributing to the innovative work and scientific impact that the company aims for."

About Aegirbio

AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com

The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | info@eminova.se

 

Related link:
Cision